Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
Thursday, January 9, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: Precision BioSciences reported a complete clinical response in the first infant treated with ECUR-506 in an ongoing Phase 1/2 trial for Ornithine Transcarbamylase (OTC) deficiency. The treatment showed positive outcomes from three months post-exposure to the end of the six-month study period. Additionally, ECUR-506 was well tolerated, with no significant safety issues noted.
Price reaction · baseline $4.5 (2025-01-08 close) · clean, no other DTIL news in the window
day 0 close
+26.7%
day 1
+27.6%
day 3
+16.9%
Market Sentiment Analysis
POSITIVE FACTORS
Complete clinical response observed in the first infant dosed.
ECUR-506 was well tolerated with no significant safety concerns.
The trial demonstrates promising results for OTC deficiency treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Treatment with ECUR-506 resulted in a complete clinical response from three months post exposure to the end of study (six months post exposure) – ECUR-506 was generally well tolerated with no significant clinical safety concerns – Insertion of a functional OTC gene through ARCUS in vivo gene
Frequently Asked Questions
What is ECUR-506?
ECUR-506 is a treatment being tested for Ornithine Transcarbamylase (OTC) deficiency.
What were the results of the trial?
The trial reported a complete clinical response in the first infant dosed with ECUR-506.
How was the safety of ECUR-506 evaluated?
ECUR-506 was generally well tolerated with no significant clinical safety concerns.
What is the duration of the study?
The study duration is six months post exposure to the treatment.